Treatment methods for hypersensitive disorders
US9233140B2 · kind B2 · utility
2Cited by
32References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 10, 2010 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | Jan 13, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.